research JAK Inhibitors in Dermatology: The Promise of a New Drug Class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
Search
for
Sort by
Research
660-690 / 1000+ results
research Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
research Skin Cell Heterogeneity in Development, Wound Healing, and Cancer
Different types of skin cells play specific roles in development, healing, and cancer.
research Increased Copy Number of the TERT and TERC Telomerase Subunit Genes in Cancer Cells
Cancer cells often have more copies of TERT and TERC genes, which helps them grow and could affect patient outcomes.
research Normal Stem Cells and Cancer Stem Cells: Similar and Different
Deregulation of stem cell function is central to the development of some cancers.
research Stretching the Limits: From Homeostasis to Stem Cell Plasticity in Wound Healing and Cancer
Stem cell plasticity is crucial for wound healing but can also contribute to cancer development.
research Anti-Cancer Properties of Olive Oil Secoiridoid Phenols: A Systematic Review of In Vivo Studies
Olive oil compounds may help prevent cancer in animals, but human results are mixed.
research The E211 G>A Androgen Receptor Polymorphism Is Associated With a Decreased Risk of Metastatic Prostate Cancer and Androgenetic Alopecia
E211 G>A gene linked to lower risk of severe prostate cancer and hair loss.
research Prostate Cancer Prevention
Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.
research The Senescence–Stemness Alliance: A Cancer-Hijacked Regeneration Principle
Cancer can hijack the body's cell repair system to promote tumor growth, and targeting this process may improve cancer treatments.
research The Population Dynamics of Cancer: A Darwinian Perspective
Cancer development is like natural selection, involving mutated cells and environmental factors.
research The Ophthalmological Complications of Targeted Agents in Cancer Therapy: What Do We Need to Know as Ophthalmologists?
Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.
research Male Pattern Baldness and Prostate Cancer Risk in a Population-Based Case-Control Study
Men who start losing hair at age 30 may have a lower risk of prostate cancer.
research Long-Term Use of 5α-Reductase Inhibitors and the Risk of Male Breast Cancer
Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.
research Relationship of Early-Onset Baldness to Prostate Cancer in African-American Men
Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.
research Age-Dependent Associations Between Androgenetic Alopecia and Prostate Cancer Risk
Early balding at 40 increases prostate cancer risk.
research Cancer Risk in Patients with Alopecia Areata: A Nationwide Population-Based Matched Cohort Study
Alopecia areata patients have varied cancer risks, with some cancers being lower and others higher.
research A Pilot Study of a Grape Seed Procyanidin Extract for Lung Cancer Chemoprevention
Grape seed extract may safely and effectively help prevent lung cancer.
research Androgenetic Alopecia at Various Ages and Prostate Cancer Risk in an Equal-Access Multiethnic Case-Control Series of Veterans
Early balding, especially frontal, increases prostate cancer risk; more research needed.
research Cancer Risk by the Subtype of Alopecia
People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.
research Gemcitabine in Combination with Vinorelbine in Elderly Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer
The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.
research Understanding the Role of Sex Hormones in Cancer for the Transgender Community
Hormone therapy affects cancer risks in transgender individuals differently than in cisgender people, and more research is needed to understand these risks and improve cancer screening guidelines.
research Finasteride Treatment and Male Breast Cancer: A Register-Based Cohort Study in Four Nordic Countries
Finasteride use may increase the risk of male breast cancer.
research Estrogen Deprivation Effects of Endocrine Therapy in Breast Cancer Patients: Incidence, Management and Outcome
Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.
research Finasteride Use and Risk of Male Breast Cancer: A Case-Control Study Using Individual-Level Registry Data from Denmark, Finland, and Sweden
Finasteride use is not clearly linked to an increased risk of male breast cancer.
research Small Cell Lung Cancer: Results of a Phase II Study of 1,2,4-Triglycidylurazol
The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
research Redefining The Crown: Approaching Chemotherapy-Induced Alopecia Among Black Patients With Breast Cancer
Oncologists should better understand the unique impact of hair loss on Black breast cancer patients to offer more compassionate care.
research Targeting the Undifferentiated State of Cancer
Less differentiated melanoma cells are more vulnerable to a type of cell death, which could improve cancer treatments.
research Early-Onset Baldness and the Risk of Aggressive Prostate Cancer: Findings from a Case-Control Study
Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.
research Cancer Chemotherapy: An Introduction
The book concludes that despite progress, cancer drug treatments have not met the expectations set in the 1960s and 1970s.